We are live on ! Find out more
WCBA

Weaver C. Barksdale & Associates Portfolio holdings

AUM $105M
1-Year Est. Return 13.81%
This Fund
S&P 500
This Quarter Est. Return
-1.4%
1 Year Est. Return
+13.81%
3 Year Est. Return
+40.08%
5 Year Est. Return
10 Year Est. Return
AUM
$107M
AUM Growth
-$6.45M
Cap. Flow
-$3.31M
Cap. Flow %
-3.09%
Top 10 Hldgs %
20.92%
Holding
63
New
1
Increased
5
Reduced
55
Closed
1

Top Sells

Rank Stock Value
1
DGX icon
Quest Diagnostics
DGX
+$2.27M
2
MRK icon
Merck
MRK
+$119K
3
AMP icon
Ameriprise Financial
AMP
+$117K
4
NXST icon
Nexstar Media Group
NXST
+$114K
5
UL icon
Unilever
UL
+$106K

Sector Composition

Rank Sector Weight
1 Financials 19.82%
2 Healthcare 15.66%
3 Industrials 11.14%
4 Energy 9.77%
5 Technology 9.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MPC icon
51
Marathon Petroleum
MPC
$94.5B
$1.43M 1.34%
10,607
-514
-5% -$64.3K
TRP icon
52
TC Energy
TRP
$66.3B
$1.39M 1.3%
35,711
-1,409
-4% -$57.3K
VZ icon
53
Verizon
VZ
$196B
$1.37M 1.28%
35,311
-1,429
-4% -$56.4K
TSN icon
54
Tyson Foods
TSN
$19.9B
$1.26M 1.18%
21,302
-1,026
-5% -$63K
MDT icon
55
Medtronic
MDT
$116B
$1.22M 1.14%
15,181
-691
-4% -$56.3K
TROW icon
56
T. Rowe Price
TROW
$24.3B
$1.07M 1%
9,503
-455
-5% -$52K
KEY icon
57
KeyCorp
KEY
$24.3B
$1.02M 0.95%
81,378
-3,937
-5% -$66.5K
OHI icon
58
Omega Healthcare
OHI
$13.8B
$976K 0.91%
35,590
-1,680
-5% -$46.8K
TFC icon
59
Truist Financial
TFC
$63.9B
$966K 0.9%
28,325
-1,181
-4% -$51.6K
T icon
60
AT&T
T
$168B
$877K 0.82%
45,541
-2,207
-5% -$42.2K
CAH icon
61
Cardinal Health
CAH
$56.3B
$237K 0.22%
3,133
CI icon
62
Cigna
CI
$72.4B
$204K 0.19%
797
-6
-0.7% -$1.75K
DGX icon
63
Quest Diagnostics
DGX
$26.2B
-14,508
Closed -$2.27M

Similar funds

Weaver C. Barksdale & Associates's Q1 2023 Portfolio in Review

As of Q1 2023, Weaver C. Barksdale & Associates held 63 positions worth $107M, down 5.7% from $113M the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Weaver C. Barksdale & Associates withdrew a net $3.31M in Q1 2023, closing 1 position and reducing 55 holdings. Its most notable exit was Quest Diagnostics, an estimated $2.27M position sold in full.

By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 21% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Weaver C. Barksdale & Associates opened a new position in LyondellBasell Industries worth $1.98M.

  • Weaver C. Barksdale & Associates's largest Q1 2023 buy was LyondellBasell Industries: 21,044 shares worth $1.98M.
  • Weaver C. Barksdale & Associates added most to Charles Schwab in Q1 2023, an estimated $523K increase.
  • Weaver C. Barksdale & Associates's biggest Q1 2023 reduction was Merck, cutting an estimated $119K.
  • Weaver C. Barksdale & Associates fully exited Quest Diagnostics in Q1 2023, selling an estimated $2.27M.
  • Weaver C. Barksdale & Associates's ten largest holdings make up 21% of its $107M portfolio in Q1 2023.
  • Weaver C. Barksdale & Associates opened 1 new position and closed 1 in Q1 2023.
  • Weaver C. Barksdale & Associates's portfolio value fell 5.7% quarter-over-quarter to $107M.

Based on Weaver C. Barksdale & Associates's 13F filing for Q1 2023, filed 12 May 2023.